Penicillamine
Cuprimine, Depen, Penicillamine (penicillamine) is a small molecule pharmaceutical. Penicillamine was first approved as Depen on 1982-01-01. It is used to treat biliary liver cirrhosis, cystinuria, hepatolenticular degeneration, lead poisoning, and mercury poisoning amongst others in the USA. It is known to target delta-type opioid receptor and solute carrier organic anion transporter family member 1C1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Cuprimine, Depen, Penicillamine (discontinued: Cuprimine, Luxzyla, Penicillamine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Penicillamine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DEPEN | Mylan | N-019854 RX | 1982-01-01 | 1 products, RLD, RS |
| CUPRIMINE | Bausch Health Companies | N-019853 RX | 1982-01-01 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cuprimine | New Drug Application | 2020-10-01 |
| depen | New Drug Application | 2023-07-19 |
| penicillamine | ANDA | 2024-09-24 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
16 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatolenticular degeneration | D006527 | Orphanet_905 | E83.01 | 1 | — | 3 | 1 | 3 | 8 |
| Cystinuria | D003555 | — | E72.01 | — | — | — | 1 | 1 | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | 1 | — | — | 1 |
| Arthritis | D001168 | HP_0001369 | M05-M14 | — | — | 1 | — | — | 1 |
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | 1 | 1 | — | — | 1 |
| Lead poisoning | D007855 | — | T56.0 | — | 1 | 1 | — | — | 1 |
| Poisoning | D011041 | EFO_0008546 | T65.91 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Arteriovenous fistula | D001164 | — | Q27.3 | — | 1 | — | — | — | 1 |
| Fistula | D005402 | — | — | — | 1 | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | 1 | — | — | — | 1 |
| Central nervous system neoplasms | D016543 | — | — | — | 1 | — | — | — | 1 |
| Nervous system neoplasms | D009423 | — | — | — | 1 | — | — | — | 1 |
| Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Head and neck neoplasms | D006258 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Systemic scleroderma | D012595 | EFO_0000717 | M34.0 | — | — | — | — | 1 | 1 |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Penicillamine |
| INN | penicillamine |
| Description | D-penicillamine is an optically active form of penicillamine having D-configuration. Pharmaceutical form (L-form is toxic) of chelating agent used to treat heavy metal poisoning. It has a role as a chelator, an antirheumatic drug, a drug allergen and a copper chelator. It is a penicillamine and a non-proteinogenic alpha-amino acid. It is an enantiomer of a L-penicillamine. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(S)[C@@H](N)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 52-67-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1430 |
| ChEBI ID | 7959 |
| PubChem CID | 5852 |
| DrugBank | DB00859 |
| UNII ID | GNN1DV99GX (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Penicillamine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 11,771 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cuprimine, Depen, Penicillamine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
668 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use